The efficacy of brentuximab vedotin (BV), an anti-CD30 monoclonal antibody, has been significant in treating R/R EBV + and CD30-positive non-Hodgkin lymphomas, with an ORR of 48% and a median response duration of 10.1 months [26]. Here, TNFRSF8 is linked to non-Hodgkin lymphoma.